Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.
about
Recent developments of protein kinase inhibitors as potential AD therapeuticsCyclin B1/Cdk1 binds and phosphorylates Filamin A and regulates its ability to cross-link actinPhosphorylation of threonine 61 by cyclin a/Cdk1 triggers degradation of stem-loop binding protein at the end of S phaseAntiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cellsCyclin dependent kinase 2 and the regulation of human progesterone receptor activityProtein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryoteMultiple phosphorylation events control mitotic degradation of the muscle transcription factor Myf5.Bcl-2 antagonists: a proof of concept for CLL therapyScreening marine resources to find novel chemical inhibitors of disease-relevant protein kinasesTRPC6 channel translocation into phagosomal membrane augments phagosomal functionCDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsSubstituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer ActivitiesEfficient activation of reconstructed rat embryos by cyclin-dependent kinase inhibitorsAftins increase amyloid-β42, lower amyloid-β38, and do not alter amyloid-β40 extracellular production in vitro: toward a chemical model of Alzheimer's disease?Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity.Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress.Ionizing radiation-dependent and independent phosphorylation of the 32-kDa subunit of replication protein A during mitosisRoscovitine binds to novel L-channel (CaV1.2) sites that separately affect activation and inactivation8-Amino-adenosine inhibits multiple mechanisms of transcription.An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3Roscovitine protects murine Leydig cells from lipopolysaccharide-induced inflammationSynthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist.Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic FibrosisCDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.Transformations of the natural cytokinin N6-isopentenyladenine in aqueous acidic media: structural aspects.Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts.Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors.Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanismPharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice.Cell cycle activation and spinal cord injury.The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - RoscovitineCyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice.Amide-controlled, one-pot synthesis of tri-substituted purines generates structural diversity and analogues with trypanocidal activity.Cyclin-Dependent Kinase Inhibitors as Anticancer TherapeuticsSites and roles of phosphorylation of the human cytomegalovirus DNA polymerase subunit UL44.Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation.The Dynamics and Regulatory Mechanism of Pronuclear H3k9me2 Asymmetry in Mouse ZygotesStrategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.
P2860
Q21129481-7B81EA31-77CB-4238-B701-6BF1F8C50886Q24301678-0A456ACF-215C-4E31-AE22-996911F2938BQ24646532-935D0683-1411-49F5-AF85-848A8A0EC639Q24653228-95FB9EBE-EB6D-45EA-AD5D-254E8BB1CE64Q24678662-D074E7EA-8CB3-4613-9F46-BD6544BF96F9Q24792290-1E7E576B-538A-4682-B50A-633B8C28E20FQ24814111-E24FFDEB-2C2F-4F1C-9CDD-7D493F8DD216Q26823996-5D3FB598-E772-4E68-A654-A3786692FB6FQ27026168-792F88AB-2384-4A08-BFDB-5D830E8F037DQ27317729-5D984707-D707-4560-A7CF-1EADC9969884Q27670943-37DCDBEE-CB41-46F1-B968-6B29458665B9Q27675842-0FB666C2-0F6A-4E8E-A46F-B2312A3D0CF1Q28473284-F9832D1F-E41A-435D-9F65-384D23C23836Q28828789-C31DB8C4-27C4-44B1-A495-783E68C3F720Q31098941-E31EA6CC-2528-4E94-B3DD-4B8A9329815AQ33402476-4528A804-94BE-4377-845F-F45DC7878824Q33492639-35895151-F08F-462D-9D20-80FBE22D2348Q33581333-515562AC-BE1A-4CDC-8301-422366041FB7Q33590629-1377FB42-9885-4A82-A21A-C1ECE93E15D8Q33688195-161BD95C-E820-49D3-A5FE-EB1CD687ADD8Q33724078-E853F998-A212-48E6-8A40-9EB8345CB61AQ33752856-559F96F5-7855-4F3F-94B7-3CE9CF8A101AQ33857503-F89E2962-5273-4059-9472-F7D72D8BA708Q33864755-772BAEDF-547B-4E39-94AE-7FF77AE69173Q33943343-BC74E639-3210-4F7B-BCA5-3450B6206A51Q34122676-0CC2E520-18D6-49FA-A1FA-08B70E18B865Q34365839-5CDF5ECA-924B-4428-8AD8-5EC8BD1FB08AQ34489708-8BF8E4B9-3C45-4DD8-A464-04A1B7DADDA4Q34555921-6C9E78CE-4569-448B-AB6F-DCCCB519DF1DQ34954019-D7D4D733-BFDC-4BAC-A694-DA93B9BD7398Q35002296-FA873013-A18B-4609-B93E-7DACE15055EFQ35006482-6B898994-1B3F-42D2-A26C-661729F39E0DQ35062145-08B5E604-04D3-432C-851A-E32BE78CC952Q35103069-3345897D-7496-4C38-B303-21DF9C35EE1BQ35577807-51E0FEDB-9E2E-4341-9D90-0A4A178660C6Q36186117-C5856382-FDD4-4103-B76C-D988435E5532Q36212341-AEB157BC-3F56-42B2-9A41-34B8FEA39605Q36281964-DBAC60A6-7B4D-46DB-A998-1C25182B66B5Q36350569-E074E0DA-F34F-4DB4-896C-027CFDC9C992Q36372894-219F8711-ED4B-4A23-A951-501C05CB5721
P2860
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Roscovitine and other purines ...... sh oocytes to clinical trials.
@ast
Roscovitine and other purines ...... sh oocytes to clinical trials.
@en
type
label
Roscovitine and other purines ...... sh oocytes to clinical trials.
@ast
Roscovitine and other purines ...... sh oocytes to clinical trials.
@en
prefLabel
Roscovitine and other purines ...... sh oocytes to clinical trials.
@ast
Roscovitine and other purines ...... sh oocytes to clinical trials.
@en
P356
P1476
Roscovitine and other purines ...... sh oocytes to clinical trials.
@en
P2093
Eric Raymond
Laurent Meijer
P304
P356
10.1021/AR0201198
P407
P577
2003-06-01T00:00:00Z